November 2024

SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha–particle emitting radioisotope, actinium–225, for potential cancer treatments The two sides aim to submit an Investi

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: